CDT Equity Inc. (CDTTW)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Peers in industry
CDT Equity Inc. has no peer companies in this window.
Recent press releases
CDT Equity Inc. has not issued a press release in this window.
SEC filings
All filings →CDT Equity Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →CDT Equity Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at CDT Equity Inc.
All people →No officers or directors have been indexed for CDT Equity Inc..